comparemela.com

Latest Breaking News On - Paull nguyen - Page 1 : comparemela.com

Winners of the ASTRO-Sumitomo Pharma-Pfizer Alliance New Combination Therapy Challenge Announced

Researchers seek new ways to treat prostate cancer using relugolix in combination with radiation therapy

Xinglei shenPaull nguyenJames yuSumitomo pharmaShang jui wangPfizer alliance new combination relugolixSumitomo pharma america incAstro myovant sciencesYale school of medicinePfizer allianceAmerican society for radiation oncologyOhio state universityUniversity of kansas medical centerAmerican societyRadiation oncologyMyovant sciences

AAP and Apalutamide May Improve Outcomes in Subgroup of Prostate Cancer Patients

AAP and apalutamide may improve outcomes vs bicalutamide in a subgroup of prostate cancer patients receiving ADT and salvage RT after RP.

United statesDana farber cancer institutePaull nguyenHarvard medical schoolCancers symposium

Prostate Cancer Subgroup May Benefit From Intensified Therapy

In a subset of patients with high-risk prostate cancer, the combination of abiraterone acetate plus prednisone (AAP) and apalutamide may improve outcomes when added to salvage radiation therapy.

United statesWashington universityDana farber cancer instituteTyler seibertAstellas pharmaPaull nguyenJeffm michalskiVarian medical systemsMyovant sciencesAmerican society of radiation oncologyHarvard medical schoolBoston scientificUniversity of california san diegoEuropean society of medical oncology congressGe healthcareHarvard medical

AAP and Apalutamide May Improve Outcomes in Subgroup of Prostate Cancer Patients

AAP and apalutamide may improve outcomes vs bicalutamide in a subgroup of prostate cancer patients receiving ADT and salvage RT after RP.

United statesDana farber cancer institutePaull nguyenHarvard medical schoolCancers symposium

Data Published in The Red Journal Validate Prognostic Value of Veracyte s Decipher Prostate Genomic Classifier for Men with High-Risk Prostate Cancer Seite 1

15.02.2023 - Veracyte, Inc. (Nasdaq: VCYT) today announced that data published in the International Journal of Radiation Oncology, Biology, Physics (aka, “The Red Journal”) demonstrate that the company’s Decipher Prostate Genomic Classifier can improve risk . Seite 1

Paull nguyenDana farber brigham cancer centerNational cancer instituteClinical researchHarvard medical schoolDepartment of radiation oncologyNational comprehensive cancer networkRadiation oncologyBrigham cancer centerDecipher prostateDecipher prostate genomic classifierNational comprehensiveCancer network

vimarsana © 2020. All Rights Reserved.